Prescription Required(Save Upto 85%)
KADCYLA 160MG INJECTION contains Ado-Trastuzumab Emtansine which belongs to the group of medicines called Antibody-Drug Conjugates. it is a prescription medication used in the treatment of early as well as metastatic breast cancer.
It is a combination of two drugs: trastuzumab, which is an antibody that targets HER2 receptors, and Emtansine, which is a chemotherapy drug that kills cancer cells.
It is indicated to treat breast cancer in the early stages as well as advanced stages where patients develop recurrence within six months of chemotherapy treatment.
This medication acts against tumors that produce more than the normal amount of a certain protein (known as HER2 protein).
Before taking it, tell your doctor if you have heart disease, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using.
Ado-trastuzumab Emtansine (Kadcyla 160mg Injection) works by combining the targeting ability of trastuzumab, which binds to HER2-positive cancer cells, with the cell-killing effects of emtansine, a chemotherapy drug.
Once this medication binds to the HER2-positive cancer cells, it releases emtansine, which then enters the cancer cells and destroys them. This process helps to slow down or stop the growth of cancer, reducing the size of tumors and potentially extending the patient's life.
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
For treating early stage breast cancer, Kadcyla treatment follows a 21-day cycle. You’ll receive a dose of 3.6 mg/kg once every 21 days (3 weeks).
You may have up to 14 cycles of Kadcyla. How many cycles you will receive depends on whether the drug is working effectively for you or causing serious side effects.
Your doctor will monitor how you’re doing with Kadcyla treatment for as long as you’re receiving the medication. In some cases, you may need a dose reduction. Your doctor will discuss with you your exact dosage and any dosage changes.
For treating metastatic breast cancer, Kadcyla treatment follows a 21-day cycle. Your dosage will likely start at 3.6 mg/kg once every 3 weeks.
You’ll receive infusions for as long as the drug is working to treat your cancer and you don’t have serious side effects. Your doctor will monitor you carefully during treatment.
Ans : The cure rate of cancer depends upon the severity of the disease. However, KADCYLA 100MG INJECTION acts by preventing the abnormal growth and multiplication of cancer cells in the body, which may help in curing cancer completely.
Ans : Kadcyla 160mg Injection can cause temporary infertility in some patients, particularly women. If fertility preservation is a concern for you, discuss this with your healthcare provider before starting treatment.
Ans :Ado-Trastuzumab Emtansine is a type of chemotherapy, but it is designed to target HER2-positive cancer cells specifically, which may result in fewer side effects than traditional chemotherapy. Additionally, it is given as a single medication, rather than as a combination of drugs.
Ans : Kadcyla 160mg Injection may be used in combination with other cancer treatments, such as chemotherapy or targeted therapies. Your healthcare provider can help determine the best treatment plan for you based on your individual needs and medical history.
Ans :KADCYLA 160MG INJECTION may make you feel tired easily. This is because, it reduces the levels of red blood cells in your blood and may make you anemic. Consult your doctor if you experience tiredness after receiving KADCYLA 160MG INJECTION. Tiredness can also occur if you have any pre-existing disease conditions such as liver or kidney impairment while taking this medicine.
Ans :KADCYLA 160MG INJECTION may make you feel tired or dizzy. Therefore, do not drive or operate any heavy tools or machines if your ability is affected by KADCYLA 160MG INJECTION.
